Tech Company Financing Transactions
Mercy BioAnalytics Funding Round
Novalis LifeSciences, American Cancer Society and BrightEdge participated in a $41 million Series A funding round for Mercy BioAnalytics. The financing round was announced on 4/3/2023.
Transaction Overview
Company Name
Announced On
4/3/2023
Transaction Type
Venture Equity
Amount
$41,000,000
Round
Series A
Investors
Proceeds Purpose
The company intends to use the funds to advance development and commercialization of its search Halo test, for high-risk lung cancer screening, its lead clinical indication, and to advance clinical programs in additional indications, including ovarian cancer.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
22 Strathmore Road 415
Natick, MA 01760
USA
Natick, MA 01760
USA
Phone
Undisclosed
Website
Email Address
Overview
Mercy BioAnalytics is on a mission to save lives and relieve suffering across the globe through the early detection of cancer. We have developed a novel liquid biopsy assay platform which interrogates tumor-derived extracellular vesicles, which are abundant in blood and carry information about their cell of origin, enabling detection of cancer even in at the earliest stages.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Dawn Mattoon
Browse more venture capital transactions:
Prev: 4/3/2023: LandVault venture capital transaction
Next: 4/3/2023: entrio venture capital transaction
Share this article
About Our VC Transactions Data
We do our best to report on tech company VC transactions. All VC database entries on this site are sourced from news reports and company announcements. The data is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs